Filing Analysis
Solana Company (HSDT) filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2026. The filing serves as a formal notice that a press release containing these results was issued on August 14, 2026.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2026.
- Filing date: August 14, 2026.
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
Solana Company has entered into an Amended and Restated Sales Agreement to significantly increase its 'at-the-market' (ATM) offering capacity. The company expanded the aggregate gross sales price of shares it can sell from $92.8 million to $250 million.
🚩 Red Flags
- Significant increase in potential share dilution (increasing the cap to $250M is a substantial amount relative to typical micro-cap equity bases)
- Heavy reliance on ATM offerings for capital suggests a need for continuous liquidity
📋 Key Facts
- Agreement date: May 29, 2026
- Offering capacity increased from $92.8 million to $250 million
- Co-sales agents are Clear Street LLC and Maxim Group LLC
- Company has already raised $24,657,697.51 under the prior sales agreement
- Agents' commissions are set at up to 3.00% of aggregate gross proceeds
- Company agreed to reimburse agents for legal expenses up to $75,000
Solana Company reported the voting results of its Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected six directors, ratified the appointment of CBIZ CPAs P.C. as the independent auditor for 2026, and reconstituted the audit committee.
🚩 Red Flags
- High concentration of executive duties: Agustina Gani Tjandrasuwita holds four key officer positions simultaneously (CFO, COO, Treasurer, and Secretary), which is a common governance risk in micro-cap companies.
📋 Key Facts
- Elected four directors (Joseph Chee, Blane Walter, Edward M. Straw, Cosmo Jiang) and two additional directors (Michel Lee, Sergio Mello) to serve one-year terms.
- Ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,738,836 votes in favor.
- Reconstituted the audit committee of the Board of Directors to consist of Blane Walter (Chair), Edward M. Straw, and Michel Lee.
- Agustina Gani Tjandrasuwita signed the filing as CFO, COO, Treasurer, and Secretary.
Solana Co (HSDT) reported its financial results for the fiscal quarter ended March 31, 2026. The filing includes a press release as an exhibit detailing the company's quarterly performance.
🚩 Red Flags
- Inconsistency in registrant name: The header identifies the company as 'SOLANA COMPANY' while the signature block identifies the registrant as 'HELIUS MEDICAL TECHNOLOGIES, INC.'
📋 Key Facts
- Announced financial results for the fiscal quarter ended March 31, 2026
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- A press release dated May 15, 2026, was furnished as Exhibit 99.1
- The filing was signed by Agustina Gani Tjandrasuwita, Chief Operating Officer
Solana Co (HSDT) raised approximately $7.9 million through a registered direct offering of 3,076,922 shares at $2.60 per share. The offering is uniquely structured with a Put Option agreement that allows investors to force a share repurchase at a 7% IRR premium under specific conditions, including delisting notices or financial ratio breaches.
🚩 Red Flags
- Put option agreement creates a potential mandatory cash outflow/liability for the company.
- Put option triggers include 'issuance of a delisting notice', suggesting a high risk of non-compliance with exchange requirements.
- Speculative use of proceeds for 'accumulating SOL' (cryptocurrency) rather than core business operations.
- Tight financial covenant (30% net debt to total capitalization) which, if breached, triggers the put option.
📋 Key Facts
- Issued 3,076,922 shares of Class A common stock at an offering price of $2.60 per share.
- Expected net proceeds of approximately $7.9 million.
- Use of proceeds includes 'accumulating SOL' (cryptocurrency), working capital, and strategic initiatives.
- Entered into Put Option Agreements allowing purchasers to require the company to repurchase shares at the offering price plus a 7.0% IRR per annum.
- Put Option triggers include 12-month and 18-month anniversaries, net debt to total capitalization ratio exceeding 30%, or receipt of a delisting notice.
Solana Co announced the departure of two directors and the immediate appointment of two new directors with significant expertise in digital assets and global investment banking. The board size was increased from seven to nine members as part of this transition ahead of the 2026 Annual Meeting.
📋 Key Facts
- Directors Sherrie Perkins and Paul Buckman will not stand for re-election at the May 21, 2026, Annual Meeting.
- The Board of Directors was expanded from seven to nine members on April 23, 2026.
- Michel Lee, co-founder of Hashkey Group and Cybertech Partners, was appointed to the board.
- Sergio Mello, global head of stablecoin solutions at Anchorage Digital and former Reddit advisor, was appointed to the board.
- The company stated there were no disagreements with the departing directors regarding operations, policies, or practices.
On April 8, 2026, Solana Company and Chief Medical Officer Dr. Antonella Favit-Van Pelt mutually agreed to her immediate separation from the company. The company will provide a lump-sum separation payment of $875,000 in exchange for a release of claims.
🚩 Red Flags
- Immediate effective date of departure (April 8, 2026) suggests a lack of transition period.
- Significant cash outlay of $875,000 for a single executive departure in a micro-cap context.
📋 Key Facts
- Dr. Antonella Favit-Van Pelt resigned as Chief Medical Officer effective April 8, 2026.
- The separation was described as a mutual agreement between the executive and the company.
- The company is obligated to pay a $875,000 lump sum separation payment within ten business days.
- The executive agreed to a waiver and release of all claims against the company.
- Dr. Favit-Van Pelt remains bound by confidential information and invention assignment provisions.
Solana Co (HSDT) has appointed Agustina 'Madelene' Gani Tjandrasuwita as Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026. Ms. Tjandrasuwita brings significant executive experience from the blockchain and cryptocurrency sectors, having previously held senior finance roles at Hedera Hashgraph, Aptos Labs, and Gemini.
📋 Key Facts
- Agustina Tjandrasuwita appointed as COO and Deputy CFO effective April 6, 2026.
- Annual base salary set at $350,000 with a target cash bonus of 40% of base salary.
- Target range for aggregate annual bonus and incentives is $300,000 to $500,000.
- One-time sign-on option award of $75,000 in Class A common stock, vesting over four years.
- The appointee previously served as CFO of Hedera Hashgraph (2024-2026) and Head of Finance at Aptos Labs (2022-2024).
- The filing contains a clerical error, labeling Item 5.02 as 'Results of Operations and Financial Condition' instead of the standard 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers'.
Solana Co (formerly Helius Medical Technologies) issued a press release on March 30, 2026, announcing its financial results for the fiscal quarter and full year ended December 31, 2025.
📋 Key Facts
- The company reported financial results for the period ended December 31, 2025.
- The registrant was formerly known as Helius Medical Technologies, Inc.
- The information was furnished under Item 2.02 and is not deemed 'filed' for regulatory purposes.
- The filing includes a press release as Exhibit 99.1.
Solana Company (formerly Helius Medical Technologies) filed an 8-K under Item 8.01 to disclose its current share count: 52,802,604 shares of common stock outstanding plus 23,930,181 pre-funded warrants. The filing highlights significant potential dilution (~45%) from the warrant overhang and follows a corporate name change from a medical device company to one sharing the name of a prominent cryptocurrency blockchain.
🚩 Red Flags
- Large pre-funded warrant overhang representing ~45% potential dilution relative to current outstanding shares
- Corporate name change from medical technology company to 'Solana Company' — shares the name of a major cryptocurrency blockchain (Solana/SOL), raising concerns about a hype-driven pivot or rebranding strategy
- Stand-alone share count disclosure via 8-K may signal upcoming capital markets activity (secondary offering, warrant exercise, or further dilution)
- Name change combined with share/warrant disclosure pattern is common among micro-caps attempting to attract speculative retail interest
📋 Key Facts
- 52,802,604 shares of common stock issued and outstanding as of February 20, 2026
- 23,930,181 pre-funded warrants to purchase common stock are issued and outstanding
- Total fully-diluted share count is approximately 76.7 million shares (~45% dilution from warrants alone)
- Company recently rebranded from Helius Medical Technologies, Inc. to Solana Company
- Listed on Nasdaq under ticker HSDT; incorporated in Delaware
- Signed by CFO Jeffrey S. Mathiesen
Solana Company (formerly Helius Medical Technologies, Inc.) has issued an 8-K to announce its financial results for the quarter ended September 30, 2025, alongside a business update.
🚩 Red Flags
- No specific financial data or negative indicators were provided in the text of this 8-K; it serves only as a placeholder for an attached press release (Exhibit 99.1).
📋 Key Facts
- The filing is a standard announcement of quarterly financial results and a business update.
- Reporting period: Quarter ended September 30, 2025.
- Company name change noted: Formerly known as Helius Medical Technologies, Inc.
- Filing date: November 18, 2025.
Solana Company (formerly Helius Medical Technologies) announced a board reshuffle involving the election of Cosmo Jiang and the resignation of Executive Chairman Jeffrey S. Mathiesen. Additionally, the company authorized a significant $100 million stock repurchase program.
🚩 Red Flags
- Resignation of Executive Chairman Jeffrey S. Mathiesen immediately following the election of a new director (though stated as not due to disagreement).
- Multiple material items in a single filing (Board changes, employment agreement, and massive repurchase authorization) can indicate high volatility or rapid corporate restructuring.
📋 Key Facts
- Cosmo Jiang was elected to the Board of Directors on October 30, 2025.
- Executive Chairman Jeffrey S. Mathiesen resigned from the Board effective October 30, 2025.
- The company's subsidiary, Solana Company (Hong Kong) Limited, entered into an employment agreement with Joseph Chee featuring a $525,000 base salary and a $61,250 sign-on bonus.
- The Board authorized a stock repurchase program for up to $100 million of Class A common stock.
Solana Company (formerly Helius Medical Technologies, Inc.) filed an 8-K to disclose a corporate presentation and a press release pursuant to Regulation FD. The filing serves as a vehicle to disseminate updated investor information via the company's website.
📋 Key Facts
- Company name changed from Helius Medical Technologies, Inc. to Solana Company.
- Filed on November 3, 2025.
- Issued an 'Investor Update' corporate presentation (Exhibit 99.1).
- Issued a press release (Exhibit 99.2) under Item 7.01.
Solana Company (formerly Helius Medical Technologies) held a special meeting of stockholders on October 30, 2025, where shareholders approved several key proposals. These include the election of a new director and the issuance of common stock via warrants to strategic advisors and cryptocurrency-related instruments.
🚩 Red Flags
- Issuance of common stock via warrants to specific entities (Pantera Capital Management LP and Summer Wisdom Holdings Limited) requires Nasdaq approval, indicating potential dilution or non-standard financing terms.
- Significant use of cryptocurrency (Solana/SOL) as consideration for private placement increases volatility and balance sheet complexity.
📋 Key Facts
- Special Meeting held on October 30, 2025.
- Cosmo Jiang elected to the Board of Directors (21,737,666 votes in favor).
- Shareholders approved issuance of shares upon exercise of Strategic Advisor Warrants issued to Pantera Capital Management LP and Summer Wisdom Holdings Limited per Nasdaq Rule 5635(a).
- Shareholders approved issuance of shares via Cryptocurrency Pre-Funded and Stapled Warrants related to the acceptance of Solana (SOL) as consideration in a private placement.
- Approved an amendment to increase the 2022 Equity Incentive Plan by 4,000,000 shares.
- Quorum was met with 21,742,341 shares represented out of 40,299,220 outstanding.
Solana Company (formerly Helius Medical Technologies, Inc.) issued a correction to a press release regarding its SOL token holdings. The company clarified that its SOL holdings increased by approximately 0.1 million tokens since October 6, 2025, rather than the 1 million previously stated.
🚩 Red Flags
- Inaccurate reporting of material assets (SOL token holdings) in a press release.
📋 Key Facts
- Company name changed from Helius Medical Technologies, Inc. to Solana Company.
- Correction issued on October 29, 2025, regarding an error in a previous press release.
- The error involved the amount of SOL tokens held by the company.
- Actual increase in SOL holdings: ~0.1 million since Oct 6, 2025 (previously reported as 1 million).
Solana Company (formerly Helius Medical Technologies, Inc.) filed an 8-K to provide notice of a press release issued on October 20, 2025, pursuant to Regulation FD.
📋 Key Facts
- Company name change: Formerly known as Helius Medical Technologies, Inc.
- The filing is made under Item 7.01 (Regulation FD Disclosure).
- A press release dated October 20, 2025, was issued and incorporated by reference as Exhibit 99.1.
- The report contains forward-looking statements subject to significant risk factors.
Solana Company (formerly Helius Medical Technologies, Inc.) announced the immediate resignation of its independent auditor, Baker Tilly US, LLP, and the appointment of CBIZ CPAs P.C. as its new auditor for the fiscal year ending December 31, 2025.
🚩 Red Flags
- Auditor change (resignation of existing firm)
- Existing 'going concern' language in previous audit reports for FY2023 and FY2024
- Immediate resignation of the auditor can sometimes indicate friction, though no formal disagreement was reported.
📋 Key Facts
- Baker Tilly US, LLP resigned as the Company's independent registered public accounting firm effective October 15, 2025.
- CBIZ CPAs P.C. has been appointed as the new independent auditor for the fiscal year ending December 31, 2025.
- Previous audit reports for FY2023 and FY2024 contained explanatory paragraphs expressing substantial doubt regarding the Company's ability to continue as a going concern.
- The company stated there were no disagreements with Baker Tilly regarding accounting principles or auditing procedures.
Helius Medical Technologies, Inc. has changed its corporate name to Solana Company, effective September 29, 2025. The company also announced a non-binding letter of intent with the Solana Foundation regarding a partnership and purchase option rights for SOL.
🚩 Red Flags
- Name change often signals a pivot in business model or attempt to rebrand following significant corporate shifts.
📋 Key Facts
- Company name changed from Helius Medical Technologies, Inc. to Solana Company.
- Name change effective as of 8:00 a.m. ET on September 29, 2025.
- The Board approved the name change and amended bylaws without stockholder approval per Delaware General Corporation Law.
- Entered into a non-binding letter of intent (LOI) with the Solana Foundation.
- The LOI includes terms for a future partnership and purchase option rights related to SOL.
Helius Medical Technologies entered into side letter agreements with its CEO and CFO to pay one-time discretionary cash bonuses totaling $1.5 million. These payments are designed to prevent a 'Change in Control' trigger following recent offerings, effectively offsetting potential severance or change-in-control payouts.
🚩 Red Flags
- Significant discretionary cash bonuses ($1.5M total) paid to top executives immediately following a capital raise/offering.
- Use of side letters to circumvent 'Change in Control' clauses in executive employment agreements.
- Potential conflict of interest regarding the timing and structure of executive compensation relative to corporate transactions.
📋 Key Facts
- CEO Dane C. Andreeff to receive a $890,000 discretionary cash bonus.
- CFO Jeffrey S. Mathiesen to receive a $610,000 discretionary cash bonus.
- The bonuses are intended to offset any severance, equity, or retirement benefits the officers would otherwise be entitled to.
- The side letters ensure that recent offerings (from Sept 18, 2025) do not constitute a 'Change in Control' under their employment agreements.
- Company filed an FDA 510(k) submission for label expansion of its Portable Neuromodulation Stimulator for gait and balance deficit in chronic stroke patients.
Helius Medical Technologies, Inc. filed an 8-K to announce the issuance of a press release on September 22, 2025. The filing itself contains no substantive financial or corporate changes and serves as a placeholder for the attached exhibit.
📋 Key Facts
- The company issued a press release on September 22, 2025.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- No specific material event details are contained within the text of this 8-K beyond the reference to Exhibit 99.1.
Helius Medical Technologies announced a massive $508.7 million private placement involving common stock, pre-funded warrants, and stapled warrants, with consideration accepted in USD, USDC, USDT, or SOL tokens. The company intends to use the proceeds to establish a Solana (SOL) treasury operation.
🚩 Red Flags
- Massive dilution: Issuance of tens of millions of shares and warrants at a significant premium/discount structure.
- Extreme pivot in business model: Shifting from medical technology to a Solana-based cryptocurrency treasury strategy.
- Highly complex capital structure involving stapled warrants, pre-funded warrants, and crypto-denominated assets.
- Advisor Warrants issued at $0.001 per share represent extreme dilution for existing shareholders.
📋 Key Facts
- Total gross proceeds from Offerings: approximately $508.7 million.
- Cash Offering includes 37,825,277 shares of Class A common stock at $6.881/share and various warrants.
- Cryptocurrency Offering involves pre-funded and stapled warrants with consideration in SOL tokens.
- Strategic Advisor Agreement signed with Pantera Capital Management LP and Summer Wisdom Holdings Limited.
- Pantera and Summer to receive warrants to purchase common stock at $0.001 per share (performance/base advisor warrants).
- Company plans to use net proceeds to acquire Solana (SOL) tokens via open market purchases.
- Joseph Chee appointed as Executive Chairman of the Board.
Helius Medical Technologies has entered into a new sales agreement with Clear Street LLC and Maxim Group LLC to facilitate an 'at-the-market' (ATM) offering of up to $92.8 million in Class A common stock. This follows a previous termination of a similar agreement with Roth Capital Partners.
🚩 Red Flags
- Significant potential dilution: The company is seeking to raise up to $92.8 million via ATM offering, which typically results in continuous downward pressure on the stock price.
- High volume of authorized shares: Stockholders recently approved increasing authorized shares to 800 million, providing significant headroom for further dilutive issuances.
📋 Key Facts
- Entered into Sales Agreement on September 15, 2025, with Clear Street LLC and Maxim Group LLC as co-sales agents.
- The offering allows for the sale of Class A common stock up to an aggregate price of $92.8 million.
- The offering is being conducted via an 'at the market' (ATM) method under a previously effective S-3 shelf registration statement.
- Agents will receive commissions of up to 3.00% of gross proceeds.
- Company approved an increase in authorized shares to 800,000,000 at a special meeting on May 23, 2025.
Helius Medical Technologies is conducting a dual-track private placement involving both cash (USD/Stablecoins) and cryptocurrency (SOL tokens). The offering includes pre-funded warrants with extremely low exercise prices ($0.001) and stapled warrants, alongside the engagement of strategic advisors who will receive significant equity via performance-based warrants.
🚩 Red Flags
- Extremely low exercise price ($0.001) for pre-funded warrants creates massive potential dilution.
- Complex 'stapled' and 'pre-funded' warrant structures are often used in highly dilutive financing rounds.
- The company is pivoting/expanding into cryptocurrency (SOL treasury), which introduces significant volatility risk to the core business model.
- Strategic Advisor Summer Wisdom Holdings Limited is controlled by Joseph Chee, who is expected to become Executive Chairman, indicating a potential related-party transaction and change in control dynamics.
📋 Key Facts
- Cash Offering: Sale of Class A common stock, pre-funded warrants (exercise price $6.879), and stapled warrants (exercise price $10.134).
- Cryptocurrency Offering: Sale of pre-funded warrants and stapled warrants in exchange for Unlocked or Locked SOL tokens.
- Use of Proceeds: To fund the acquisition of Solana (SOL) via open market purchases, establish a Solana treasury, and working capital.
- Strategic Advisor Agreement: Engagement of Pantera Capital Management LP and Summer Wisdom Holdings Limited for 2 years.
- Equity Compensation: Advisors to receive warrants equal to 7% and 3% of the aggregate shares issued in the offering, respectively.
- Closing Date: Expected on or about September 18, 2025.
Helius Medical Technologies announced positive results from its Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program (SRP), meeting primary endpoints for gait and balance improvement. The company plans to submit an FDA application for a new indication in patients with chronic stroke symptoms under its existing Breakthrough Device Designation.
🚩 Red Flags
- Forward-looking statements include significant risks regarding capital requirements, ability to secure Medicare/Medicaid coverage, and potential cash burn (operating costs).
📋 Key Facts
- The double-blind randomized clinical trial met the primary endpoint of statistically significant improvements in gait/balance deficit compared to sham therapy.
- The SRP included 159 enrolled patients, with 130 completing the full 12-week treatment and 12-week follow-up phase.
- Studies confirmed minimal incidence of adverse events and good treatment tolerability.
- The company intends to seek FDA indication for gait and balance deficit in chronic stroke patients.
- Clinical trials were conducted across 10 sites in the US and Canada.
Helius Medical Technologies has regained compliance with Nasdaq's minimum stockholders' equity requirement ($2.5 million) as of July 7, 2025. However, the company is now subject to a Mandatory Panel Monitor until July 7, 2026.
🚩 Red Flags
- Mandatory Panel Monitor: The company is under heightened scrutiny by Nasdaq until July 2026.
- Zero-tolerance policy for future equity deficiencies during the monitoring period; no opportunity for additional cure periods if non-compliance occurs again.
- History of delisting risk (previously failed both bid price and equity requirements).
📋 Key Facts
- Company regained compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Requirement) on July 7, 2025.
- The company previously regained compliance with the Minimum Bid Price Requirement on June 3, 2025.
- A Mandatory Panel Monitor has been imposed for a one-year period ending July 7, 2026.
- Under Nasdaq Listing Rule 5815(d)(4)(B), any subsequent failure to meet the Equity Requirement during the monitoring period will result in an immediate 'Delist Determination Letter' without the possibility of a compliance plan or cure period.
Helius Medical Technologies, Inc. has filed an updated Prospectus Supplement to facilitate the 'at-the-market' (ATM) sale of up to $25 million in common stock through Roth Capital Partners, LLC.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $25 million ATM offering capacity.
📋 Key Facts
- The offering is part of a Sales Agreement originally entered into on June 23, 2023.
- The maximum aggregate amount of the offering is $25 million.
- Shares will be sold via an 'at-the-market' (ATM) offering mechanism under Rule 415(a)(4).
- Proceeds are intended for working capital, general corporate purposes, commercialization efforts, and R&D activities.
- The sale is conducted pursuant to a previously filed Form S-3 Registration Statement (File No. 333-270433).
Helius Medical Technologies, Inc. has approved a 1-for-50 reverse stock split to comply with Nasdaq listing requirements. The split is effective as of June 30, 2025, and trading will resume on a split-adjusted basis on July 1, 2025.
🚩 Red Flags
- Reverse stock split is a common defensive measure to avoid Nasdaq delisting due to low share price.
- Significant reduction in outstanding shares (from 33.8M to 0.7M) indicates extreme dilution/capital structure management.
📋 Key Facts
- Reverse stock split ratio: 1-for-50
- Effective date: June 30, 2025, at 5:00 p.m. ET
- Trading resumes on a split-adjusted basis: July 1, 2025
- Outstanding shares expected to decrease from ~33.8 million to ~0.7 million
- Authorized shares remain unchanged at 150 million
- New CUSIP number: 42328V 876
- The split was approved by stockholders on May 23, 2025
Helius Medical Technologies provides an update regarding its Nasdaq compliance status following a successful public offering. The company has increased its stockholders' equity above the $2.5 million minimum requirement and is awaiting formal confirmation from Nasdaq.
🚩 Red Flags
- History of non-compliance with Nasdaq minimum stockholders' equity requirements.
- Extreme proximity to delisting deadline (June 30, 2025) at time of filing.
📋 Key Facts
- Company was non-compliant with Nasdaq Listing Rule 5550(b)(1) due to stockholders' equity falling below $2.5 million as of Dec 31, 2024.
- Nasdaq granted an extension until June 30, 2025, to regain compliance.
- On June 6, 2025, the company completed a public offering resulting in net proceeds of approximately $8.1 million.
- As of June 17, 2025, unaudited interim consolidated balance sheet shows stockholders' equity meets the >$2.5 million requirement.
Helius Medical Technologies announced the implementation of an Equity Plan Amendment following a recent public offering. This amendment increases the total number of shares available under the 2022 Equity Incentive Plan by 7.1 million shares.
🚩 Red Flags
- Significant increase in share pool (7.1 million shares) suggests potential future dilution for existing shareholders.
- The trigger for the equity expansion was a recent 'Public Offering,' which often implies a need for immediate liquidity or capital infusion.
📋 Key Facts
- Stockholders approved the Equity Plan Amendment on May 23, 2025.
- The amendment was triggered by the closing of a Public Offering occurring after May 15, 2025.
- As of June 16, 2025 (the 10th day following the offering), the aggregate number of shares available under the Plan increased to 7.1 million shares.
Helius Medical Technologies, Inc. has received formal notification from Nasdaq confirming it has regained compliance with the minimum bid price requirement of $1.00 per share.
🚩 Red Flags
- Previous non-compliance with minimum bid price requirement indicates past extreme volatility or significant downward pressure on stock price.
📋 Key Facts
- Received formal notification from The Nasdaq Stock Market LLC on June 3, 2025.
- Regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The rule requires issuers to maintain a closing bid price of at least $1.00 per share.
Helius Medical Technologies, Inc. (HSDT) held a special meeting on May 23, 2025, where stockholders approved several critical measures, most notably a reverse stock split intended to maintain Nasdaq compliance.
🚩 Red Flags
- Reverse stock split approved to avoid delisting (Nasdaq compliance issue).
- Significant increase in authorized shares (up to 800M) suggests potential massive dilution.
- Approval of a large share issuance (148.6M shares) for 'potential financing' indicates urgent need for capital.
📋 Key Facts
- Stockholders approved a reverse stock split with a ratio between 1-to-2 and 1-to-250, at the Board's discretion.
- The reverse split is specifically intended to enable compliance with Nasdaq listing requirements.
- Approved an increase in authorized shares of Common Stock to up to 800,000,000 shares.
- Approved the issuance of up to 148,621,326 shares for a potential financing pursuant to Nasdaq rules.
- Approved amendments to the 2022 Equity Incentive Plan.
Helius Medical Technologies, Inc. has announced a 1-for-15 reverse stock split to comply with Nasdaq listing requirements. The split is effective as of May 1, 2025, and trading will resume on a split-adjusted basis on May 2, 2025.
🚩 Red Flags
- Reverse stock split executed specifically to comply with Nasdaq continued listing requirements (indicates potential risk of delisting if share price remains low)
- Significant reduction in the number of outstanding shares
📋 Key Facts
- Reverse split ratio: 1-for-15
- Effective date/time: May 1, 2025, at 5:00 p.m. ET
- Trading resumes on a split-adjusted basis: May 2, 2025
- Outstanding shares reduction: From approximately 7.92 million to approximately 0.5 million
- Authorized shares remain unchanged at 150 million
- New CUSIP number: 42328V 884
- The split was approved by stockholders on April 21, 2025
Helius Medical Technologies entered into a securities purchase agreement to issue $1.56 million in 20% original issue discount (OID) promissory notes and 1,320,150 shares of common stock. The financing is intended for working capital but carries highly aggressive terms including an extremely short maturity date.
🚩 Red Flags
- Extremely short maturity date (approx. 3 months from closing)
- Maturity is tied to the successful completion of a Form S-1 registration, creating a 'death spiral' pressure
- High OID (20%) and potential default interest rate (20%) indicate high cost of capital/distressed financing
- Significant dilution: 1.32M shares being issued for $1.3M gross proceeds suggests a very low share price
- The use of 'unsecured' promissory notes increases risk to the company's balance sheet flexibility
📋 Key Facts
- Aggregate principal amount of Notes: $1,560,000
- Original Issue Discount (OID): 20%
- Expected gross proceeds: $1,300,000 before fees
- Shares to be issued: 1,320,150 shares of common stock
- Maturity Date: July 24, 2025, or the closing of the next Form S-1 registered offering
- Interest rate: 0% until an Event of Default, at which point it jumps to 20.0% per annum
- Placement Agent: Maxim Group LLC (7% commission + legal fee reimbursement)
At its annual meeting on April 21, 2025, Helius Medical Technologies (HSDT) stockholders approved a significant reverse stock split and the issuance of shares related to warrant inducements. The reverse split is specifically intended to address Nasdaq listing compliance requirements.
🚩 Red Flags
- Reverse stock split approved to avoid Nasdaq delisting (high indicator of distress).
- Significant dilution potential via the approval of 'Warrant Inducement Share Issuance' involving up to 6.2M shares.
- The need for a reverse split often indicates a critically low share price.
📋 Key Facts
- Annual meeting held on April 21, 2025.
- Stockholders approved a reverse stock split with a ratio between 1-for-2 and 1-for-30 (to be determined by the Board).
- The reverse split is intended to enable compliance with Nasdaq listing requirements.
- Stockholders approved the issuance of up to 6,213,888 shares upon exercise of existing Series C and Series D warrants.
- Six directors were elected for one-year terms.
- Baker Tilly US, LLP was ratified as the independent auditor for FY2025.
Helius Medical Technologies received notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, with equity falling below $2.5 million. While a hearing was held and an extension was granted until June 30, 2025, the company remains in violation of multiple listing standards.
🚩 Red Flags
- Delisting notice for failure to meet minimum stockholders' equity requirement.
- Failure to meet the $5,000,000 initial listing requirement for Nasdaq Capital Market.
- History of non-compliance with Minimum Bid Price Requirement.
- Ineligibility for standard 180-day extensions due to low equity levels.
📋 Key Facts
- Nasdaq notified the company on March 31, 2025, that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (Stockholders' Equity Requirement).
- Company stockholders' equity fell below $2.5 million as of the fiscal year ended December 31, 2024.
- The company previously failed to meet the Minimum Bid Price Requirement and was ineligible for a second 180-day compliance period due to insufficient equity.
- Nasdaq granted an extension until June 30, 2025, following a hearing on March 18, 2025, to regain compliance with both the Minimum Bid Price and Stockholders' Equity requirements.
Helius Medical Technologies received a delisting notice from Nasdaq following its failure to regain compliance with the $1.00 minimum bid price requirement by the February 5, 2025 deadline. The company intends to appeal the decision via a hearing before the Nasdaq Hearings Panel to stay the delisting.
🚩 Red Flags
- Delisting notice from Nasdaq (Failure to meet $1.00 minimum bid price).
- Dilutive warrant inducement program involving over 6 million new warrants.
- Significant liquidity/compliance pressure evidenced by the need for a warrant exercise inducement at a discount.
📋 Key Facts
- Nasdaq issued a letter on February 7, 2025, confirming continued non-compliance with the Minimum Bid Price Requirement (Rule 5550(a)(2)).
- The company's common stock faces delisting from the Nasdaq Capital Market unless an appeal is filed.
- The company intends to request a hearing before the Nasdaq Hearings Panel to stay delisting and present a compliance plan.
- On January 21, 2025, the company entered into warrant exercise inducement letters to raise cash by offering reduced exercise prices ($0.751) for existing warrants.
- The inducement involves issuing up to 6,213,888 new Series C and D warrants, subject to stockholder approval.
- The Annual Meeting of Stockholders is scheduled for April 21, 2025.
Helius Medical Technologies entered into inducement letters with existing warrant holders to encourage the exercise of Series A and B warrants at a reduced price. In exchange, the company will issue new Series C and D warrants, resulting in significant potential dilution.
🚩 Red Flags
- Significant Dilution: The issuance of over 6.2 million new warrant shares represents substantial potential dilution for existing shareholders.
- Warrant Inducement: Using discounted warrants to induce exercise is often a sign of liquidity pressure or a need for immediate cash.
- Contingent Approval Required: The transaction relies on shareholder approval, creating execution risk.
📋 Key Facts
- Existing Warrants: Holders agreed to exercise 4,971,110 shares at a reduced price of $0.751 per share.
- Expected Proceeds: Approximately $3.7 million in gross proceeds from the exercise.
- New Issuance: Company will issue Series C and D Inducement Warrants to purchase up to 6,213,888 shares.
- Shareholder Approval: The issuance of Inducement Warrants is contingent upon obtaining stockholder approval via a special meeting within 90 days.
- Lock-up/Restrictions: Company agreed not to issue common stock or file new registration statements for 60 days and no variable rate transactions for 75 days.
Helius Medical Technologies announced that CMS has posted final Medicare reimbursement rates for its PoNS Controller (HCPCS Code A4593). The final rates are consistent with the preliminary determinations previously shared.
📋 Key Facts
- CMS finalized the Medicare Durable Medical Equipment, Prosthetics, Orthotics, and Supplies fee schedule payment rates on January 13, 2025.
- The reimbursement rate applies to the PoNS Controller (HCPCS Code A4593).
- Final rates are consistent with preliminary reimbursement determinations.
Helius Medical Technologies announced its first PoNS System sale to the VA Healthcare System via a distributor. The transaction represents a significant milestone in the company's commercialization efforts within the government healthcare sector.
📋 Key Facts
- First PoNS System sale completed to the VA Healthcare System.
- Sale was facilitated through distributor Lovell Government Services.
- Total contracted price: $23,844.
- Price breakdown: $16,499 for the PoNS Controller and $7,345 for the PoNS Mouthpiece.
Helius Medical Technologies has initiated a strategic review process to explore alternatives for maximizing stockholder value, having engaged B. Riley Securities as financial advisor. Additionally, the company is actively contesting CMS pricing determinations regarding its PoNS Controller/Mouthpiece.
🚩 Red Flags
- Initiation of 'strategic alternatives' often signals potential sale, merger, or restructuring due to liquidity or performance pressures.
- Regulatory uncertainty regarding Medicare (CMS) reimbursement pricing for its primary product/service.
📋 Key Facts
- Company has engaged B. Riley Securities as a financial advisor to explore strategic alternatives.
- The company is rebutting a CMS preliminary pricing determination for the PoNS Controller.
- CMS previously issued a final pricing determination of $2,963.30 for the PoNS Mouthpiece, effective January 1, 2025.
- Helius has requested a meeting with CMS to attempt to revisit/renegotiate the pricing before the January 1 deadline.
Helius Medical Technologies, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2024 and scheduled a conference call to discuss corporate highlights.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results and corporate highlights.
Helius Medical Technologies received a notice from Nasdaq stating it is non-compliant with the minimum bid price requirement because its stock closed below $1.00 for 30 consecutive business days. The company has until February 5, 2025, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Stock price sustained below $1.00 (Penny Stock territory)
- Risk of delisting if compliance is not met by February 5, 2025
📋 Key Facts
- Received notice from Nasdaq Listing Qualifications Staff on August 9, 2024.
- Non-compliance due to Class A common stock closing bid price being below $1.00 for the prior 30 consecutive business days.
- Compliance period of 180 calendar days ends February 5, 2025.
- To regain compliance, the stock must close at or above $1.00 per share for a minimum of 10 consecutive business days.
Helius Medical Technologies, Inc. reported the results of its annual meeting held on June 27, 2024, which included the election of six directors and approval of an amendment to the 2022 Equity Incentive Plan. The company also ratified Baker Tilly US, LLP as its independent auditor for the fiscal year ending December 31, 2024.
🚩 Red Flags
- Significant dilution potential due to the increase in shares available under the Equity Incentive Plan and the automatic annual 5% increases through 2029.
📋 Key Facts
- Stockholders approved an amendment to the 2022 Equity Incentive Plan on June 27, 2024.
- The Amendment increases the aggregate number of shares available under the plan by 2,089,000 new shares.
- The Amendment includes a provision for automatic annual increases of 5% of Fully Diluted Shares from 2025 through 2029.
- The maximum number of shares issuable pursuant to Incentive Stock Options was increased to 5,000,000 shares.
- Six directors were elected to one-year terms ending at the 2025 annual meeting.
- Baker Tilly US, LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2024.
Helius Medical Technologies has regained compliance with Nasdaq's minimum stockholders' equity requirement following a financing completed on May 9, 2024. The company is no longer under delisting threat regarding this specific rule.
🚩 Red Flags
- Historical non-compliance with minimum stockholders' equity requirements (Rule 5550(b)(1)) indicates past liquidity or capitalization distress.
📋 Key Facts
- Received formal notification from Nasdaq on May 31, 2024, confirming compliance with Listing Rule 5550(b)(1).
- Compliance was achieved via a financing consummated on May 9, 2024.
- The company satisfies all other applicable criteria for continued listing on the Nasdaq Capital Market.
- The specific delisting matter regarding stockholders' equity is now closed.
Helius Medical Technologies, Inc. announced the scheduling of its 2024 Annual Meeting of Stockholders for June 27, 2024. The filing also establishes deadlines for stockholder proposals and director nominations.
🚩 Red Flags
- Meeting date shift: The filing notes the meeting date was moved by more than 30 days from the previous year's anniversary, which requires specific disclosure under SEC rules.
📋 Key Facts
- Annual Meeting date set for Thursday, June 27, 2024.
- Record date for the Annual Meeting was May 28, 2024.
- Deadline for submission of stockholder proposals or director nominations is close of business on June 10, 2024.
- The meeting date has been changed by more than 30 days from the anniversary of the 2023 meeting.
Helius Medical Technologies, Inc. issued an 8-K to announce the release of its financial results for the quarter ended March 31, 2024. The filing serves as a formal notification that earnings data and corporate highlights are being made public via a press release.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes an announcement of a conference call to discuss financial results and recent corporate highlights.
- Financial results are provided in Exhibit 99.1.
Helius Medical Technologies completed a registered public offering of common stock and warrants to raise approximately $6.4 million in gross proceeds. The offering was strategically timed to resolve a Nasdaq minimum stockholders' equity deficiency.
🚩 Red Flags
- Significant dilution: The issuance of millions of warrants (Series A and B) represents substantial potential future dilution for existing shareholders.
- Nasdaq compliance history: The company was previously notified of non-compliance with Nasdaq Rule 5550(b) due to insufficient stockholders' equity ($2.5M minimum requirement).
- High cost of capital: The placement agent fee (7%) and issuance of additional warrants to the agent increase the effective cost of the financing.
📋 Key Facts
- Gross proceeds from the public offering are approximately $6.4 million before fees.
- The offering includes 704,999 shares of Class A common stock and 2,147,222 pre-funded warrants at a price of $2.25 per share/warrant unit.
- Series A Warrants (up to 2,852,221 shares) have an exercise price of $2.25 and expire in five years.
- Series B Warrants (up to 2,852,221 shares) have an exercise price of $2.25 and expire in twelve months.
- Placement Agent (Craig-Hallum Capital Group LLC) received a 7% cash fee plus warrants for 142,611 shares at $2.475 per share.
- The offering closed on May 9, 2024.
Helius Medical Technologies announced preliminary CMS proposed fee schedule payment rates for its PoNS Controller and PoNS Mouthpiece. The reimbursement rates will be discussed at a public meeting on May 29, 2024.
🚩 Red Flags
- Reimbursement rates are 'preliminary' and subject to change following the May 29th meeting.
- The PoNS Mouthpiece reimbursement ($3,075.53) represents a significant haircut from the $4,500 cash pay price.
📋 Key Facts
- CMS published proposed fee schedule payment rates for the PoNS Controller (HCPCS Code A4593) and PoNS Mouthpiece (HCPCS code A4594).
- PoNS Controller reimbursement is mapped to existing code E0745, resulting in a capped fee of $1,206.53.
- PoNS Mouthpiece pricing is based on the cash pay price of $4,500, resulting in a total capped payment of $3,075.53.
- The final rates are subject to discussion at the CMS bi-annual HCPCS public meeting scheduled for May 29, 2024.
Helius Medical Technologies received a notice from Nasdaq stating it is in violation of minimum stockholders' equity requirements. The company's equity fell below the $2.5 million threshold as reported in its FY2023 10-K.
🚩 Red Flags
- Delisting notice (non-compliance with minimum stockholders' equity)
- Failure to meet alternative compliance standards
- Critical capital deficiency indicated by equity falling below $2.5M threshold
📋 Key Facts
- Received written notice from Nasdaq on April 4, 2024.
- Violation of Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity.
- Stockholders' equity fell below the required $2.5 million threshold as of December 31, 2023.
- The company has until May 20, 2024, to submit a plan to regain compliance.
- If a plan is accepted, Nasdaq may grant up to a 180-day extension to evidence compliance.
Helius Medical Technologies, Inc. issued an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Financial results announced for the quarter and year ended December 31, 2023.
- Report filed on March 28, 2024.
- Includes a press release as Exhibit 99.1 regarding financial performance and corporate highlights.
Helius Medical Technologies, Inc. has adopted Second Amended and Restated Bylaws effective March 12, 2024. The amendments primarily focus on updating governance procedures, including quorum requirements and compliance with SEC universal proxy rules.
🚩 Red Flags
- Reduction of quorum requirement from a majority to one-third can make it easier for minority shareholders to pass resolutions, which may be viewed as defensive or governance-related maneuvering.
📋 Key Facts
- The Board of Directors approved the Second Amended and Restated Bylaws on March 12, 2024.
- Quorum requirement for stockholder meetings reduced from a majority to one-third of outstanding voting shares.
- Bylaws updated to comply with SEC universal proxy rules regarding proxy solicitation.
- New requirements established for stockholders/groups calling special meetings to nominate directors (must hold 10% of votes).
- Enhanced disclosure requirements for stockholder nominations and proposals.
Helius Medical Technologies announced that CMS has assigned HCPCS Level II codes to its PoNS controller and mouthpiece, effective April 1, 2024. This is a critical regulatory milestone for reimbursement, with the company expecting potential reimbursement rates by October 1, 2024.
🚩 Red Flags
- Forward-looking statements regarding reimbursement rates are speculative and not guaranteed.
- Risk factors mentioned in the disclaimer include 'availability of funds' and 'use of cash', suggesting potential liquidity concerns common in micro-cap med-tech firms.
📋 Key Facts
- CMS assigned Healthcare Common Procedure Coding System (HCPCS) Level II codes to PoNS controller and mouthpiece.
- The new HCPCS codes become effective on April 1, 2024.
- Company plans to submit additional information to CMS regarding reimbursement economics ahead of summer public meetings.
- Potential for Medicare/Medicaid reimbursement amounts to be determined by October 1, 2024.
Helius Medical Technologies reported the completion of an At-The-Market (ATM) offering program activity. The company sold 173,336 shares of common stock between October 2023 and February 2024 to raise capital.
🚩 Red Flags
- Dilution of existing shareholders through ATM offering activity.
📋 Key Facts
- Sold $1.6 million worth of Class A common stock via ATM program with Roth Capital Partners, LLC.
- Period covered: October 3, 2023, to February 9, 2024.
- Total shares issued/sold: 173,336 shares.
- Average sale price per share: $9.17.
- Net proceeds to the Company: $1.5 million.
- As of Feb 9, 2024, outstanding common stock is 886,743 shares.